Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (12)

Company Market Cap Price
NVO Novo Nordisk A/S
At-home administration devices (auto-injector devices) for GLP-1 therapies are part of Novo Nordisk’s delivery platform.
$226.31B
$50.38
+0.41%
BDX Becton, Dickinson and Company
BD develops auto‑injector devices (wearable injectors) for home/at‑home administration of biologics.
$57.58B
$199.99
-0.45%
TAK Takeda Pharmaceutical Company Limited
ENTYVIO Pen demonstrates the use of auto-injector devices for at-home administration of biologics.
$45.43B
$14.52
+1.33%
WST West Pharmaceutical Services, Inc.
Auto-Injector Devices are a key product category in West's GLP-1 and other injectable platforms.
$19.24B
$269.50
+0.73%
ROIV Roivant Sciences Ltd.
Auto-injector devices enabling at-home administration for IMVT-1402, fitting Auto-Injector Devices.
$15.09B
$21.93
-0.75%
ATR AptarGroup, Inc.
Aptar has auto-injector devices/platforms for at-home administration of injectable therapies.
$8.00B
$120.85
-0.51%
HALO Halozyme Therapeutics, Inc.
Halozyme is expanding its portfolio of auto-injector devices to enable at-home/self-administration of therapies.
$7.28B
$62.65
+0.71%
STVN Stevanato Group S.p.A.
Develops and manufactures Auto-Injector Devices for at-home/self-administration of injectable therapies.
$6.31B
$20.98
+0.77%
AMRX Amneal Pharmaceuticals, Inc.
DHE autoinjector (Brekiya) approval signals involvement in auto-injector device delivery systems.
$3.83B
$12.36
+1.23%
KE Kimball Electronics, Inc.
Auto-injector devices represent a differentiated medical device assembly capability.
$734.79M
$30.26
-0.26%
SCPH scPharmaceuticals Inc.
Auto-Injector Devices reflect the SCP-111 autoinjector program for at-home administration.
$299.33M
$5.67
ASRT Assertio Holdings, Inc.
Otrexup is an auto-injector device, fitting the Auto-Injector Devices category.
$73.32M
$0.74
-2.86%

Loading company comparison...

Loading research report...

NVO Novo Nordisk A/S

Novo Nordisk Launches Ozempic in India, Targeting a $24‑Per‑Week Price Point

Dec 13, 2025
NVO Novo Nordisk A/S

EMA Grants Positive Opinion for Novo Nordisk’s 7.2‑mg Wegovy, Expanding EU Obesity Portfolio

Dec 12, 2025
AMRX Amneal Pharmaceuticals, Inc.

Amneal Reports Strong Interim Phase 4 Results for CREXONT in Parkinson’s Disease

Dec 05, 2025
HALO Halozyme Therapeutics, Inc.

Halozyme Wins German Court Injunction Blocking Merck’s Keytruda SC in Germany

Dec 05, 2025
BDX Becton, Dickinson and Company

BD and ChemoGLO Partner to Expand Hazardous‑Drug Contamination Testing

Dec 04, 2025
BDX Becton, Dickinson and Company

BD Unveils Three‑ and Four‑Laser FACSDiscover A8 Configurations, Expanding Spectral Flow Cytometry and Imaging Access

Dec 03, 2025
AMRX Amneal Pharmaceuticals, Inc.

Amneal Secures FDA Approval for Generic Albuterol Inhalation Aerosol

Dec 02, 2025
ATR AptarGroup, Inc.

AptarGroup Acquires Sommaplast in $35 Million Deal to Expand Oral Dosing Pharma Packaging

Dec 02, 2025
NVO Novo Nordisk A/S

Novo Nordisk Submits FDA Application for 7.2‑mg Wegovy Dose

Nov 27, 2025
NVO Novo Nordisk A/S

Novo Nordisk Reports Strong Phase 2 Results for Amycretin, Paving Way for 2026 Phase 3 Launch

Nov 25, 2025
BDX Becton, Dickinson and Company

BD Launches Surgiphor™ Surgical Wound Irrigation System in Europe with CE Approval

Nov 24, 2025
NVO Novo Nordisk A/S

Novo Nordisk’s Oral Semaglutide Alzheimer’s Trials Fail to Meet Primary Endpoint

Nov 24, 2025
NVO Novo Nordisk A/S

Novo Nordisk Partners with Waltz Health to Launch Direct‑to‑Employer Sales Channel for GLP‑1 Drugs

Nov 22, 2025
TAK Takeda Pharmaceutical Company Limited

FDA Investigates Fatal Antibody Reaction in Takeda’s Adzynma Blood Disorder Drug

Nov 21, 2025
TAK Takeda Pharmaceutical Company Limited

Takeda and Beacon Biosignals Expand Multi‑Year Collaboration to Accelerate Narcolepsy Diagnosis

Nov 19, 2025
HALO Halozyme Therapeutics, Inc.

Halozyme Completes Acquisition of Elektrofi, Expanding High‑Dose Drug Delivery Technology

Nov 18, 2025
BDX Becton, Dickinson and Company

BD Gains WHO Prequalification for Onclarity HPV Assay, Broadening Global Cervical Cancer Screening

Nov 17, 2025
NVO Novo Nordisk A/S

Novo Holdings to Sell 155 Million Shares of Convatec Group, Completing Exit from the Medical‑Device Company

Nov 17, 2025